Literature DB >> 7516411

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.

Y Kawakami1, S Eliyahu, K Sakaguchi, P F Robbins, L Rivoltini, J R Yannelli, E Appella, S A Rosenberg.   

Abstract

Four melanoma proteins, MART-1, gp100, tyrosinase, and tyrosinase-related protein-1 (gp75) were evaluated for recognition by HLA-A2-restricted melanoma-specific cytotoxic T lymphocytes (CTLs) derived from the tumor-infiltrating lymphocytes (TIL) of 10 different patients. 9 of 10 TIL recognized MART-1, 4 recognized gp100 (including 3 that also recognized MART-1), but none of the TIL recognized tyrosinase or gp75. Based on the known HLA-A2.1 peptide binding motifs, 23 peptides from MART-1 were synthesized in an attempt to identify the epitopes recognized by TIL. Three peptides were recognized by TIL when pulsed on T2 target cells. One of the 9-mer peptides, AAGIGILTV, was most effective in sensitizing the T2 cells for TIL lysis. This peptide was recognized by 9 of 10 HLA-A2-restricted melanoma-specific CTLs. Therefore, this peptide appears to be a very common immunogenic epitope for HLA-A2-restricted melanoma-specific TIL and may be useful for the development of immunotherapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516411      PMCID: PMC2191573          DOI: 10.1084/jem.180.1.347

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  23 in total

1.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules.

Authors:  J Ruppert; J Sidney; E Celis; R T Kubo; H M Grey; A Sette
Journal:  Cell       Date:  1993-09-10       Impact factor: 41.582

2.  Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes.

Authors:  C L Slingluff; A L Cox; R A Henderson; D F Hunt; V H Engelhard
Journal:  J Immunol       Date:  1993-04-01       Impact factor: 5.422

3.  Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes.

Authors:  W J Storkus; H J Zeh; M J Maeurer; R D Salter; M T Lotze
Journal:  J Immunol       Date:  1993-10-01       Impact factor: 5.422

4.  Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA.

Authors:  B H O'Neil; Y Kawakami; N P Restifo; J R Bennink; J W Yewdell; S A Rosenberg
Journal:  J Immunol       Date:  1993-08-01       Impact factor: 5.422

5.  Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.

Authors:  A B Bakker; M W Schreurs; A J de Boer; Y Kawakami; S A Rosenberg; G J Adema; C G Figdor
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

6.  Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.

Authors:  B Gaugler; B Van den Eynde; P van der Bruggen; P Romero; J J Gaforio; E De Plaen; B Lethé; F Brasseur; T Boon
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

7.  Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.

Authors:  A Anichini; C Maccalli; R Mortarini; S Salvi; A Mazzocchi; P Squarcina; M Herlyn; G Parmiani
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

8.  Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma.

Authors:  Y Kawakami; S A Rosenberg; M T Lotze
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

9.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Authors:  V Brichard; A Van Pel; T Wölfel; C Wölfel; E De Plaen; B Lethé; P Coulie; T Boon
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

10.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

Authors:  C Traversari; P van der Bruggen; I F Luescher; C Lurquin; P Chomez; A Van Pel; E De Plaen; A Amar-Costesec; T Boon
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

View more
  203 in total

1.  Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

Authors:  S Gnjatic; Y Nagata; E Jager; E Stockert; S Shankara; B L Roberts; G P Mazzara; S Y Lee; P R Dunbar; B Dupont; V Cerundolo; G Ritter; Y T Chen; A Knuth; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

2.  Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.

Authors:  C J Kim; T Prevette; J Cormier; W Overwijk; M Roden; N P Restifo; S A Rosenberg; F M Marincola
Journal:  J Immunother       Date:  1997-07       Impact factor: 4.456

3.  Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

Authors:  E Jäger; S Gnjatic; Y Nagata; E Stockert; D Jäger; J Karbach; A Neumann; J Rieckenberg; Y T Chen; G Ritter; E Hoffman; M Arand; L J Old; A Knuth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

4.  In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses.

Authors:  Christoph Esslinger; Laurence Chapatte; Daniela Finke; Isabelle Miconnet; Philippe Guillaume; Frédéric Lévy; H Robson MacDonald
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

Review 5.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

6.  Growth stimulation of tumor-specific cytotoxic T lymphocytes on concanavalin a-immobilized carrier beads.

Authors:  S Q Liu; L S Liu; T Ohno
Journal:  Cytotechnology       Date:  1998-01       Impact factor: 2.058

7.  Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells.

Authors:  Vinod Singh; Qingyong Ji; Lionel Feigenbaum; Robert M Leighty; Arthur A Hurwitz
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

8.  Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.

Authors:  Oleg Y Borbulevych; Francis K Insaidoo; Tiffany K Baxter; Daniel J Powell; Laura A Johnson; Nicholas P Restifo; Brian M Baker
Journal:  J Mol Biol       Date:  2007-07-26       Impact factor: 5.469

Review 9.  Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy.

Authors:  Claudia Trojaniello; Jason J Luke; Paolo A Ascierto
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

Review 10.  Antigen-specific vaccines for cancer treatment.

Authors:  Maria Tagliamonte; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.